| Contemporary use and implications of beta-blockers in patients with HFmrEF or HFpEF: the DELIVER trial A Peikert, BA Bart, M Vaduganathan, BL Claggett, IJ Kulac, MN Kosiborod, ... Heart Failure 12 (4), 631-644, 2024 | 7 | 2024 |
| Comparative effectiveness of aspirin dosing in cardiovascular disease and diabetes mellitus: a subgroup analysis of the ADAPTABLE trial DI Narcisse, H Kim, LM Wruck, AL Stebbins, D Muñoz, S Kripalani, ... Diabetes care 47 (1), 81-88, 2024 | 2 | 2024 |
| Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis P Ponikowski, RJ Mentz, AF Hernandez, J Butler, MS Khan, ... European Heart Journal 44 (48), 5077-5091, 2023 | 56 | 2023 |
| Lessons from COVID-19 for pandemic preparedness: proceedings from a multistakeholder think tank S Narayanasamy, LH Curtis, AF Hernandez, CW Woods, MA Moody, ... Clinical Infectious Diseases 77 (12), 1635-1643, 2023 | 4 | 2023 |
| Dapagliflozin and apparent treatment-resistant hypertension in heart failure with mildly reduced or preserved ejection fraction: The DELIVER Trial JW Ostrominski, M Vaduganathan, S Selvaraj, BL Claggett, ZM Miao, ... Circulation 148 (24), 1945-1957, 2023 | 4 | 2023 |
| Impact of COVID‐19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial AS Bhatt, MN Kosiborod, BL Claggett, ZM Miao, M Vaduganathan, ... European Journal of Heart Failure 25 (12), 2177-2188, 2023 | 8 | 2023 |
| Corrections & amendments O Vardeny, JC Fang, AS Desai, PS Jhund, B Claggett, M Vaduganathan, ... nature medicine 29, 3268-3272, 2023 | | 2023 |
| Baseline characteristics of patients in the randomized study to investigate the efficacy and safety of ferric carboxymaltose as treatment for heart failure with iron deficiency … J Harrington, RJ Mentz, FW Rockhold, J Garg, J Butler, CG De Pasquale, ... American Heart Journal 266, 25-31, 2023 | 3 | 2023 |
| Morbidity and Mortality Associated With Heart Failure in Acute Coronary Syndrome: A Pooled Analysis of 4 Clinical Trials NP Goodwin, RM Clare, JL Harrington, A Badjatiya, DM Wojdyla, JA Udell, ... Journal of Cardiac Failure 29 (12), 1603-1614, 2023 | 1 | 2023 |
| Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial O Vardeny, JC Fang, AS Desai, PS Jhund, B Claggett, M Vaduganathan, ... nature medicine 29 (12), 3269-3269, 2023 | | 2023 |
| Outpatient worsening among patients with mildly reduced and preserved ejection fraction heart failure in the DELIVER trial S Chatur, M Vaduganathan, BL Claggett, JW Cunningham, KF Docherty, ... Circulation 148 (22), 1735-1745, 2023 | 8 | 2023 |
| Dapagliflozin in patients with heart failure and deterioration in renal function S Chatur, M Vaduganathan, BL Claggett, FR Mc Causland, AS Desai, ... Journal of the American College of Cardiology 82 (19), 1854-1863, 2023 | 13 | 2023 |
| Effectiveness and safety of enteric-coated vs uncoated aspirin in patients with cardiovascular disease: a secondary analysis of the ADAPTABLE randomized clinical trial A Sleem, MB Effron, A Stebbins, LM Wruck, G Marquis-Gravel, D Muñoz, ... JAMA cardiology 8 (11), 1061-1069, 2023 | 2 | 2023 |
| Cardio-renal-metabolic overlap, outcomes, and dapagliflozin in heart failure with mildly reduced or preserved ejection fraction JW Ostrominski, J Thierer, BL Claggett, ZM Miao, AS Desai, PS Jhund, ... Heart Failure 11 (11), 1491-1503, 2023 | 11 | 2023 |
| Clinical and echocardiographic diversity associated with physical fitness in the Project Baseline Health Study: implications for heart failure staging N Cauwenberghs, F Haddad, MA Daubert, R Chatterjee, M Salerno, ... Journal of Cardiac Failure 29 (11), 1477-1489, 2023 | 5 | 2023 |
| Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients Treated With P2Y12 Inhibitors S Girotra, A Stebbins, L Wruck, G Marquis‐Gravel, K Gupta, P Farrehi, ... Journal of the American Heart Association 12 (20), e030385, 2023 | | 2023 |
| Cost-Effectiveness of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: The VICTORIA Randomized Clinical Trial DS Chew, Y Li, R Bigelow, PA Cowper, KJ Anstrom, MR Daniels, ... Circulation 148 (14), 1087-1098, 2023 | 3 | 2023 |
| Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to … B Besse, E Felip, RG Campelo, M Cobo, C Mascaux, A Madroszyk, ... Annals of Oncology 34 (10), 920-933, 2023 | 11 | 2023 |
| Comparison of the effectiveness and safety of 2 aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: A subgroup analysis of … K Gupta, H Mehta, H Kim, A Stebbins, LM Wruck, D Muñoz, MB Effron, ... American heart journal 264, 31-39, 2023 | 2 | 2023 |
| Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction according to polypharmacy status A Peikert, P Goyal, M Vaduganathan, BL Claggett, IJ Kulac, ZM Miao, ... Heart Failure 11 (10), 1380-1393, 2023 | 11 | 2023 |
Gregg C. FonarowUCLA Division of CardiologyVerified email at mednet.ucla.edu